GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. / Knudsen, L.B.; Agerso, H.; Bjenning, C.; Holst, J.J.
I: Drug Future, Nr. 26, 2001, s. 677-685.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Knudsen, LB, Agerso, H, Bjenning, C & Holst, JJ 2001, 'GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development', Drug Future, nr. 26, s. 677-685.
APA
Knudsen, L. B., Agerso, H., Bjenning, C., & Holst, J. J. (2001). GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drug Future, (26), 677-685.
Vancouver
Knudsen LB, Agerso H, Bjenning C, Holst JJ. GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drug Future. 2001;(26):677-685.
Author
Bibtex
@article{91cf56c074c711dbbee902004c4f4f50,
title = "GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development",
author = "L.B. Knudsen and H. Agerso and C. Bjenning and J.J. Holst",
year = "2001",
language = "English",
pages = "677--685",
journal = "Drug Future",
number = "26",
}
RIS
TY - JOUR
T1 - GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development
AU - Knudsen, L.B.
AU - Agerso, H.
AU - Bjenning, C.
AU - Holst, J.J.
PY - 2001
Y1 - 2001
M3 - Journal article
SP - 677
EP - 685
JO - Drug Future
JF - Drug Future
IS - 26
ER -
ID: 170825